DNA Sequencing Market is Expected to Reach $26,206.5 Million by 2026

ABOUT THIS REPORT

OVERVIEW

DNA Sequencing Market is expected to reach $26,206.5 million by 2026; growing at a CAGR of 18.9% till 2026.

DNA sequencing is the process of determining the sequence of nucleotides within a DNA molecule. DNA sequencing includes any method that is used to determine the order of the four bases adenine, guanine, cytosine, and thymine. DNA sequences have become essential for basic biological research, and in numerous applied fields such as biotechnology, forensic biology, medical diagnosis, virology, and biological systematics. DNA sequences diagnose different diseases such as various cancer type, characterize antibody repertoire, and can be used to guide patient treatment. DNA sequencing is used to determine the sequence of individual genes, larger genetic regions, full chromosomes, or entire genomes of any organism.

Technological advancements by the company in DNA sequencing is driving the global DNA Sequencing market. For instance, Longas Technologies Pty Ltd, a developer of Next Generation Sequencing (NGS) technologies, has introduced its Morphoseq technology. Morphoseq is a disruptive technology designed to improve the performance of industry-standard NGS platforms by increasing effective read lengths, with benefits in accuracy and cost-efficiency. Moreover, Pacific Biosciences of California, Inc., the leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, has enhanced its Sequel System, by including a new version (6.0) of its software, new SMRT Cell (1M v3) and new consumable reagents (3.0). Sequel System 6.0 improves the performance and affordability of Single Molecule, Real-Time (SMRT) Sequencing provide individual long reads with greater than 99% accuracy, increasing the throughput up to 50 Gb per SMRT Cell.

Consumable, Instrument and Service in the type segment of the market scope, the application segment is categorized into Biomarkers and Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Forensics, Others, the technology segment is divided into Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single-Molecule Real-Time Sequencing, Chain Termination Sequencing, and Nanopore Sequencing, and the end-users segment cover Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Hospitals & Clinics. The report covers the value of the global market by type, application, technology, and end-users.

The market value of consumables was USD XX million in 2019, and it is expected to reach USD XX million by 2026, growing at a CAGR of XX during 2020-2026. The advent of novel pre-sequencing products and kits for executing DNA fragmentation, target enrichment, size selection, and others would propel the growth of the segment.

North America, Europe, Asia Pacific, South America, and Middle East & Africa are taken into consideration at the global DNA sequencing Value figures. While North America is further categorized into enhancing the United States, Canada, and Mexico, Europe is split into the United Kingdom, Germany, France, Italy, and Rest of Europe. Asia-Pacific covers India, China, Japan, South Korea, and Rest of Asia Pacific in its scope. South America is bifurcated into Brazil, Argentina, and Rest of South America, with Middle East & Africa involving GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America DNA sequencing market was USD XX million in 2019, and it is predicted to reach USD XX million by 2026, growing at a CAGR of XX during the forecast period. The regulatory approval for DNA sequencing would improve the growth of the market. For instance, the United States Federal Bureau of Investigation has approved next-gen forensic DNA technology for use by forensic laboratories generating DNA profiles for upload to the National DNA Index System (NDIS).

Major players operating in the DNA sequencing industry include Abbott Laboratories, Agilent Technologies, Inc., Danaher Corporation (Beckman Coulter, Inc), F. Hoffmann-La Roche Ltd, Illumina, Inc., LI-COR Biosciences, Inc., Pacific Biosciences of California, Inc., Siemens Aktiengesellschaft, Thermo Fisher Scientific Inc., ZS Genetics, Inc.

Commercialization of regulatory approved DNA sequencing and formation of strategic collaborations are some of the few business strategies adopted by the key companies, with a focus on maintaining a competitive advantage over others. The technological advancement in DNA sequencing is a strategy adopted by Universal Sequencing Technology Corporation (‘UST’). The company has developed TELL-Seq technology for linked, long-read DNA sequencing applications. These kits allow to conveniently and effectively turn a short-read DNA sequencer into a long-read DNA sequencer.